The preclinical pharmacokinetic (PK) and pharmacodynamic (PD) studies, conducted in cynomolgus monkeys following subcutaneous and intravenous administration, demonstrated rapid downregulation of the ...

In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its innovative γδ T ...

Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg have identified a previously undocumented, organ-specific toxicity linked to CD19-targeted CAR T-cell therapy in autoimmune disease.

A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...

The FDA approved updated labeling for Carvykti (ciltacabtagene autoleucel, Janssen Biotech) to include a new boxed warning for immune effector cell-associated enterocolitis (IEC-EC). Carvykti is a ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as monotherapy and in combination with rituximab among patients with B-cell lymphomas, ...